Medios (ILM1.DE) Azione Prezzo
Medios Prezzo
Negli ultimi 19 anni Medios ha aumentato il fatturato del 43,1% all'anno, raggiungendo 2,08 miliardi EUR. L'utile per azione è cresciuto del 6,2% all'anno negli ultimi 19 anni. Per Medios, il margine netto del 0,7% risulta sostanzialmente stabile rispetto al 0,5% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Medios è 25,50 EUR, circa il 119,4% sopra il prezzo attuale di mercato. Su 11 analisti, 10 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Medios Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Medios Azione e analisi azionaria
Domande frequenti sull'azione Medios
The business model of Medios AG revolves around providing individualized specialty pharmaceuticals to patients, healthcare professionals, and partners. As a pharmaceutical company, Medios AG specializes in the development and production of patient-specific therapies, making them a key player in personalized medicine. By leveraging their comprehensive knowledge and expertise in pharmaceutical processes, Medios AG ensures that patients receive tailored treatment plans that meet their specific needs. Through partnerships with healthcare professionals and industry experts, Medios AG continuously strives to enhance the quality of patient care and improve therapeutic outcomes.
Medios AG is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Medios AG in the market are XYZ Company, ABC Corporation, and LMN Group.
Medios AG is a German pharmaceutical company founded in 2013. It specializes in the provision of innovative specialty pharmaceuticals and healthcare solutions. Over the years, Medios has established itself as a reliable and trusted partner for hospitals, clinics, and wholesalers in the healthcare industry. The company's focus lies in individualized patient care, particularly in the areas of oncology, neurology, and rare diseases. Medios AG operates with a patient-centric approach, utilizing its comprehensive expertise and strong network to ensure the availability and timely supply of life-saving medications. With its commitment to high-quality standards and commitment to customer satisfaction, Medios AG continues to solidify its position as a leading player in the pharmaceutical sector.
Medios AG, a leading provider of specialty pharmaceuticals and innovative patient-specific solutions, has achieved numerous significant milestones. The company's commitment to innovation and excellence has led to remarkable achievements, including expanding its product portfolio, establishing strategic partnerships, and achieving strong financial growth. Medios AG has successfully entered new markets, launched innovative healthcare programs, and gained recognition for its exceptional customer service. Furthermore, the company's dedication to sustainability and patient-oriented solutions has positioned Medios AG as a trusted leader in the pharmaceutical industry.
Medios AG is primarily present in Germany and its neighboring countries, including Austria and Switzerland. As a leading provider of specialty pharmaceuticals and patient-specific therapies, Medios AG focuses on supplying medicine to specialized pharmacies, hospitals, and clinics in these regions. With its robust infrastructure and extensive network, the company ensures efficient and reliable distribution of pharmaceutical products and personalized medication for patients. Medios AG's presence in these countries and regions allows it to serve the growing need for customized medicine and contribute to better healthcare outcomes for patients.
Medios AG, a renowned pharmaceutical company, embodies a set of values and a distinct corporate philosophy. With a mission to provide comprehensive specialty pharmaceutical services, Medios AG is committed to improving patients' lives through innovative solutions. The company places great importance on maintaining the highest standards of quality, safety, and reliability in its operations. Medios AG embraces a patient-centric approach, ensuring access to vital medications and individualized therapies. By fostering strong partnerships with healthcare professionals and stakeholders, Medios AG strives to contribute to sustainable healthcare systems. Upholding integrity, transparency, and responsibility, Medios AG continually demonstrates its dedication to delivering excellence in the pharmaceutical industry.
Gli analisti fissano attualmente un prezzo obiettivo medio di 24,48 EUR per l’azione Medios (mediana: 25,50 EUR), pari a +119,0 % rispetto all’ultimo prezzo. Il consenso si basa su 11 giudizi di analisti.
11 analisti valutano attualmente l’azione Medios: 10 raccomandano l’acquisto, 1 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Medios ricavi pari a 2,16 miliardi EUR e un utile per azione di 1,17 EUR.
L’azione Medios (ILM1.DE) è quotata su 9 borse, tra cui: London (0QB4.L), SIX (Zürich) (ILM1.SW), XETRA (ILM1.DE), Frankfurt (ILM1.F), München (ILM1.MU), Düsseldorf (ILM1.DU), Hamburg (ILM1.HM).
Medios AG is a publicly traded company that specializes in the trading and manufacturing of pharmaceuticals. The company operates as a provider of medication in the specialty pharmacy sector and offers professional solutions for medication supply to its customers. The company divides its offerings into three sectors: Specialty Pharma, Clinical Trial Supply, and Clinical Data Management. Medios focuses on niche markets in the specialty pharmacy sector, particularly in the trading of medications, catering to patients with rare diseases, complex therapeutic forms, and chronic conditions. The company works closely with doctors, health insurance companies, hospitals, and other healthcare providers. Medios guarantees its customers fast delivery of medications, maximum reliability in supply, and optimal customer support with its extensive assortment of pharmaceuticals. In the Clinical Trial Supply sector, Medios functions as a service provider for clinical research, supplying medications to research institutions and making them available for clinical studies as part of drug approvals. Medios relies on digital platforms and processes to ensure efficient and secure processing of orders. Additionally, Medios assists its customers with planning, preparation, and implementation of experiments and other organizational tasks during clinical trials. The Clinical Data Management sector is another important area for Medios, involving the processing of clinical data obtained during clinical studies. Medios provides comprehensive support in the evaluation of research data, utilizing modern IT systems for innovative, transparent, and efficient project processing. Medios adopts a sustainable approach in building relationships with customers and partners, leveraging modern technologies and digital solutions. With its wide-ranging offerings and extensive experience, Medios is regarded as one of the leading providers in the specialty pharmacy sector. The company is expanding both at a national and international level. In summary, Medios holds a leading position in the market as a provider of pharmaceuticals and services in the specialty pharmacy sector. With its diverse offerings, including sectors such as Specialty Pharma, Clinical Trial Supply, and Clinical Data Management, as well as collaboration with customers and partners at national and international levels, the company sets industry standards.
Il attesa fatturato di Medios ammonta a 2,16 miliardi EUR. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Medios ammonta a 28,66 Mio. EUR. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Medios è attualmente 9,94. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Medios.
Il rapporto prezzo/fatturato (P/S) di Medios è attualmente 0,13. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Medios.
Il Quality Score AlleAktien per Medios è 5/10.
L'ISIN di Medios è DE000A1MMCC8. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Medios è A1MMCC. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Medios è ILM1.DE. Con questo simbolo di borsa vengono negoziate le azioni Medios in borsa.
Azione Medios
Altre metriche e analisi di Medios in Deep Dive.
La nostra analisi azionaria dell'azione Medios include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Medios. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: